IRLAB Therapeutics has reported its full-year results for 2022, providing both a financial and an op...
Receives record DKK +2bn PPP order. Boosts an already high order book Another quality stamp for MTHH...
Q4 2022 adjusted EBITA was slightly below our expectations despite sales and gross profit being in l...
(Rättelsen avser ny länk till analysen) Veckan efter att Infracom släppte sin Q4-rapport genomför bo...
Arbetsbrist och höga sjukskrivningstal tynger kvartalet… Drivet av förvärv ökade omsättningen med 14...
Redeye comments on the outcome of warrants of series TO5B.
Redeye comments on SDS's recent announcement of progress made in its discussions with bondholders an...
Med helåret 2022 presenterat står det klart att CyberGene levererade en stark omsättningstillväxt om...
After entering three new markets in 2022, STENOCARE delivered products to a total of five countries ...
The progress in Q3’22/23 (Nov–Jan) continues to support the long term case we’re seeing in Qlucore, ...
Redeye provides an update following Heliospectra’s amended Q4'22 report, in which order intake was s...
Redeye revises its estimates after reviewing Norse Impact’s Q4 2022 report.
Redeye retains its positive view on Efecte, following a Q4 report with high growth from new sales, b...
Bricknode is a leading supplier of SaaS solutions that enable financial companies and startups to de...
Shortcut Media Group publicerade den 28 februari 2023 bolagets delårsrapport för fjärde kvartalet 20...
On February 24th, Eevia Health published the company’s quarterly report for Q4-22.
Redeye updates its view on Media and Games Invest following its Q4 2022 report.
Rapporten för det fjärde kvartalet var svag och vi kan konstatera att perioden präglades av utmaning...
Redeye provides a brief take on Integrum’s Q3 report, and we note a -20% deviation from our sales es...
